KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses: 2010-2020

Historic Other Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 9 years, with Dec 2020 value amounting to $122.4 million.

  • Regeneron Pharmaceuticals' Other Accumulated Expenses rose 44.00% to $122.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $122.4 million, marking a year-over-year increase of 44.00%. This contributed to the annual value of $122.4 million for FY2020, which is 44.00% up from last year.
  • As of FY2020, Regeneron Pharmaceuticals' Other Accumulated Expenses stood at $122.4 million, which was up 44.00% from $85.0 million recorded in FY2019.
  • Regeneron Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $122.4 million for FY2020, and its period low was $267,000 during FY2017.
  • For the 2-year period, Regeneron Pharmaceuticals' Other Accumulated Expenses averaged around $103.7 million, with its median value being $103.7 million (2019).
  • In the last 5 years, Regeneron Pharmaceuticals' Other Accumulated Expenses plummeted by 91.31% in 2016 and then spiked by 44.00% in 2020.
  • Yearly analysis of 4 years shows Regeneron Pharmaceuticals' Other Accumulated Expenses stood at $1.2 million in 2016, then crashed by 77.33% to $267,000 in 2017, then reached $85.0 million in 2019, then spiked by 44.00% to $122.4 million in 2020.